CNC vs PHAT: fair value comparison
Centene Corporation and Phathom Pharmaceuticals, Inc. · Updated 2026-10-19
PHAT's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, CNC currently ranks higher by quality score.
| CNC | PHAT | |
|---|---|---|
| Verdict | Overvalued | Awaiting full valuation |
| Last price | $65.36 | $6.92 |
| 12-month range | $31.80–$70.51 | $6.70–$18.08 |
| Rank by discount to fair value | #106 of 108 Healthcare | — |
| Rank by quality score | #205 of 301 Healthcare | #206 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Contracting |
| Revenue growth | Modest | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Downtrend |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: CNC fair value analysis · PHAT fair value analysis